In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 ...

The study will be carried out in partnership with The GOG Foundation and the European Network of Gynecological Oncological ...

For patients with advanced or recurrent endometrial cancer, dostarlimab plus carboplatin-paclitaxel treatment is associated ...

MUSC research to use he immune system to fight cancer shows it can be done safer, cheaper and better. An SC company pushing ...

Nivolumab plus ipilimumab did not improve OS vs chemotherapy in patients with previously untreated, unresectable/metastatic urothelial carcinoma.

Cervical cancer prevention advances with new immunotherapy findings, addressing disparities and improving outcomes for ...

A study co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that combining the immunotherapy drug ...

A study co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that combining the immunotherapy drug dostarlimab with ...

Partner presentations reinforce ability of proprietary Azymetric™ platform to develop clinically validated therapeutic antibodies; Long-term outcomes and survival data for Ziihe ...

Matulonis, MD, discusses preliminary efficacy and safety results for puxitatug samrotecan in patients with recurrent endometrial cancer ... had received prior immunotherapy,” Matulonis, chief ...

and endometrial cancer" and can also be found in “cancers of the breast, prostate, bladder and thyroid.” The immunotherapy drug works by targeting cells with this mutation, as the ...